SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-077313
Filing Date
2021-06-07
Accepted
2021-06-07 06:30:44
Documents
12
Period of Report
2021-06-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2118807d1_8k.htm   iXBRL 8-K 30654
  Complete submission text file 0001104659-21-077313.txt   209120

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210604.xsd EX-101.SCH 3214
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210604_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210604_pre.xml EX-101.PRE 22729
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2118807d1_8k_htm.xml XML 3712
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 21998160
SIC: 2834 Pharmaceutical Preparations